Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 323Lung Neoplasms 237Small Cell Lung Carcinoma 79Colorectal Neoplasms 29NSCLC 25Breast Neoplasms 22Neoplasms 16Disease 15Adenocarcinoma of Lung 15Neoplasm Metastasis 12Stomach Neoplasms 10Melanoma 10Ovarian Neoplasms 9Brain Neoplasms 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Pleural Effusion, Malignant 8Motor Activity 8Mesothelioma, Malignant 8Triple Negative Breast Neoplasms 7Head and Neck Neoplasms 7Esophageal Neoplasms 7Endometrial Neoplasms 7Multiple Pulmonary Nodules 6Mesothelioma 6Carcinoma, Hepatocellular 6Thymoma 5Small Cell Lung Cancer Extensive Stage 5SCLC, Extensive Stage 5Recurrence 5

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ALK Positive Non-small Cell Lung Cancer × Thoracic × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡